RELA and hepatocellular carcinoma: To investigate the therapeutic potential of BetA in HCC harboring the TP53R249S mutation, we determined the IC50 values of BetA across multiple TP53R249S‐overexpressing cell lines, including HepG2, Huh‐7 and iHCC.[7] Of note, RELA ablation led to an increase in the IC50 values of BetA in HepG2‐TP53R249S (Figure 7C), Huh‐7‐TP53R249S (Figure 7D) and iHCC cells (Figure 7E).